Background: Sex hormones are implicated in the development of diabetes. However, whether genetic variations in sex hormone pathways (SHPs) contribute to the risk of type 2 diabetes mellitus (T2DM) remains to be determined. This study investigated associations between genetic variations in all candidate genes in SHPs and T2DM risk among a cohort of women participating in the Women's Health Initiative (WHI). Methods: Single nucleotide polymorphisms (SNPs) located within 30 kb upstream and downstream of SHP genes were comprehensively examined in 8180 African American, 3498 Hispanic American, and 3147 European American women in the WHI. In addition, whether significant SNPs would be replicated in independent populations was examined. Results: After adjusting for age, region, and ancestry estimates and correcting for multiple testing, seven SNPs were significantly associated with the risk of T2DM among Hispanic American women were identified in the progesterone receptor (PGR) gene, with rs948516 showing the greatest significance (odds ratio 0.67; 95% confidence interval 0.57-0.78; P = 8.8 × 10 −7 ; false discovery
Introduction
Diabetes mellitus is a common and complex metabolic disease associated with serious complications and premature mortality. An accelerated increase in the prevalence of diabetes is expected globally, and particularly in developing countries, underscoring the urgent need for curbing the burden of diabetes. 1 The fundamental basis of the pathogenesis of diabetes involves the impairment of insulin action and secretion. Increasing evidence from experimental and epidemiological studies suggests that androgens, estrogens, and sex hormonebinding globulin (SHBG) play important roles in insulin resistance, impaired glucose tolerance, and the development of type 2 diabetes mellitus (T2DM) and gestational diabetes. [2] [3] [4] [5] [6] [7] Recent genetic studies have shown that single nucleotide polymorphisms (SNPs) in genes involved in sex hormone pathways (SHPs) are associated with circulating levels of sex hormones and SHBG. [8] [9] [10] [11] Thus, an investigation of the relationships between these SNPs and T2DM may provide an understanding of diabetes pathogenesis, potentially supporting the development of therapeutic or preventative strategies for diabetes. Previous genome-wide association studies (GWASs) could not identify the top signals in sex steroid pathways associated with T2DM risk. 12 However, in GWAS analyses, stringent Bonferroni correction methods are used to address multiple comparisons, which may result in missing true but relatively modest associations with T2DM. An alternative approach to reduce the number of comparisons is to analyze SNP data using the candidate gene approach, which requires strong pre-existing hypotheses on the relationship between SHPs and diabetes risk.
Therefore, the aim of the present study was to investigate the relationships between variants in SHP genes and the risk of T2DM in three large populations of African American (AA), Hispanic American (HA), and European American (EA) postmenopausal women who participated in the Women's Health Initiative (WHI)-SNP Health Association Resource (SHARe) and WHI-Genomics and Randomized Trials Network (GARNET).
Methods

Study population
The WHI is a long-term national (US) health study that focuses on strategies for preventing heart disease, breast and colorectal cancer, and osteoporotic fractures in postmenopausal women. Details on the design of the WHI have been described elsewhere. 13 The original WHI study included 161 808 postmenopausal women enrolled between 1993 and 1998. It had the following two major parts: a partial factorial randomized clinical trial (CT) and an observational study. Forty clinical centers nationwide participated in both parts of the WHI study. The WHI CT enrolled 68 132 postmenopausal women (age range 50-79 years) into trials testing three prevention strategies, whereas the observational study enrolled 93 676 women who did not participate in the CT. The observational study tracked the medical history and health habits of the participants. All participants provided written informed consent to participate in the study. The institutional review boards at all participating institutions approved the research protocols.
The WHI-SHARe included 8236 AA women (6263 controls, 1973 diabetes cases) and 3497 HA women (2881 controls, 615 diabetes cases) from the WHI CT or OS, who provided consent for DNA analysis. [14] [15] [16] The WHI-GARNET included 3147 EA women (2127 controls, 1020 diabetes cases) who had been enrolled in the WHI Hormone Therapy trial and who provided consent for DNA analysis (Table 1) . Of the approximately 27 000 women who participated in the WHI Hormone Therapy trial, incident diabetes cases and matched controls of EA women who were free of prevalent or incident diabetes, coronary heart disease, stroke, and venous thrombosis were included. The matching criteria were age (AE5 years), race/ethnicity, hysterectomy status, enrollment date (AE1.5 years), and length of follow-up (AE48 months).
For replication, we included 6320 diabetes cases and 9300 controls from among AA women included in the MEta-analysis of type 2 DIabetes in African Americans (MEDIA) Consortium (sex-combined; 15 studies). 17 Originally, 16 studies were included in the MEDIA Consortium, including the AA sample in the WHISHARe, but the WHI data were excluded from the present analysis. In addition, we used publicly available data for replication, including the trans-ethnic metaanalysis in the DIAbetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium (sex-combined; n = 110 452) 12 and the meta-analysis among Mexican populations from the Slim Initiative in Genomic Medicine for the Americas (SIGMA) Type 2 Diabetes Consortium (sex-combined; n = 8891) (http://www. type2diabetesgenetics.org/variantSearch/, accessed 4 April 2017). 18 Genotyping methods DNA was extracted from the buffy coats of blood samples collected at baseline. The Affymetrix GenomeWide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA) was used to genotype all WHISHARe samples. During the genotyping stage of the study, laboratory technicians were blinded to the disease status. For the WHI-SHARe, samples were excluded on the basis of genotyping failure and quality control (sample call rate, <95%; n = 149), relatedness (n = 56), discordance between self-identified race and genetic ancestry assessed with the EIGENSTRAT (n = 56), 12 and missing phenotypic information (n = 40). For relatedness, using concordance information to identify relatives, the relative with the highest genotyping call rate was retained, whereas other family members were excluded. In addition, SNPs were excluded if they had Hardy-Weinberg P < 10 −6 , a minor allele frequency (MAF) <0.01, or a call rate < 90%. For the WHI-GARNET participants, genotyping was performed using the Illumina HumanOmni1-Quad SNP platform (Illumina, San Diego, CA, USA). Sample-and SNP-level processing quality controls were performed using a standardized protocol at the GARNET Data Coordinating Center, University of Washington. Samples with a call rate < 98%, related individuals, or discordance between self-identified race and genetic ancestry were excluded, and SNPs were excluded if they had Hardy-Weinberg P < 10 −4 or a call rate < 98%. For the WHI-GARNET, SNPs from the 1000 Genomes Project (December 2010 release) imputed using BEAGLE software (https://faculty. washington.edu/browning/beagle/beagle.html, accessed 19 February 2018) were also analyzed, and SNPs with an MAF >5% and relatively high imputation quality (r 2 > 0.5) were included in the analysis.
Selection of genes and SNPs
The genes involved in the SHPs 19, 20 
Ascertainment of T2DM
Previous validation studies confirmed that self-reported diabetes status provides a reliable measure of diagnosed diabetes status in the WHI sample. 21, 22 Thus, in the WHI-SHARe sample, individuals were classified as T2DM patients (1973 AA, 615 HA women) if they selfreported having been diagnosed with diabetes when they were not pregnant or had received treatment for diabetes at baseline or during follow-up until 14 August 2009. We included prevalent cases of diabetes because the exposures (e.g. germline mutations) are virtually guaranteed to precede the onset of diabetes. The remaining women were considered non-cases. In the WHI-GARNET sample, 1197 individuals were classified as having incident T2DM based on self-reports during any follow-up visit before 7 July 2002 in the estrogen plus progestin trial arm, or before 29 February 2004 in the estrogen-alone trial arm.
Statistical analysis
The χ 2 test and Student's t-test were used to compare dichotomous and continuous variables between case participants and non-case participants (Table 2) . To assess the relationship between each SNP and diabetes risk, we fitted logistic regression models to estimate odds ratios (ORs), assuming an additive genetic model. This analysis included the top three principal components defining global ancestry obtained via the principal component analysis-based method, and was performed separately for each self-identified ethnic group, with additional adjustment for age (continuous), region in the WHI-SHARe (AA and HA samples), and matching factors in the WHI-GARNET (EA; Table 3 ). To correct for multiple testing, we calculated the false discovery rate (FDR) Q-values for the whole set of SNPs considered in the analysis. 23 Sensitivity analyses were conducted to estimate associations between SNPs and diabetes risk in dominant and recessive genetic models, and FDR Q < 0.05 was considered to indicate significance.
We then assessed whether SNPs found to be significant in the WHI, or their proxies, were also associated with T2DM risk in the MEDIA, SIGMA, or DIA-GRAM studies. For the MEDIA population, association analyses were conducted for each study under the additive model after adjustment for age, sex, study sites, and principal components, using logistic regression models or generalized estimating equations. The estimates were pooled using the fixed-effect model implemented in METAL. 24 The statistical methods applied for the SIGMA and DIAGRAM populations are described elsewhere. 12, 19 Statistical analyses were performed using PLINK, 
Results
Our study populations included 1973 cases and 6263 non-cases among AA women and the mean age of cases and controls were 62.2 and 61.4 years, respectively; 615 cases and 2882 non-cases among HA women and the mean age of cases and controls were 60.4 and 60.2 years, respectively; and 1020 cases and 2127 non-cases among EA women and the mean age of cases and controls were 64.0 and 65.6 years, respectively; For all ethnicities evaluated (AA, HA, and EA), the amount and intensity of physical exercise was lower, body mass index (BMI) was greater, and family history of diabetes and use of postmenopausal hormone-replacement therapy were more prevalent in case than control participants (Table 1) . In HA women, but not in AA or EA women, 116 SNPs were nominally significantly associated with diabetes risk (see Tables S1-S3 , available as Supplementary Material to this paper), and seven SNPs (rs4754732, rs948516, rs10501972, rs1942845, rs522819, rs632542, and rs485283; Table S4) in the PGR gene showed statistical significance after FDR adjustment. Of these SNPs, the rs948516 SNP in the upstream region of the PGR gene had the most significant signal (OR 0.67, 95% CI 0.57-0.78, P = 8.8 × 10 −7 , Q = 7.8 × 10 −4 ; Table 3 ). Other SNPs in high linkage disequilibrium with rs948516, including rs4754732 (complete linkage disequilibrium; D 0 = 1.0; r 2 = 1.0), were also significantly associated with diabetes risk in HA women (Fig. 1) . A conditional analysis to test which SNPs are independently associated with diabetes revealed that those SNPs originally identified as significant did not retain significant association with the risk of diabetes after conditioning on rs948516 (P-value for rs4754732 not available because of complete linkage disequilibrium with rs948516; for rs10501972, P = 0.8842; for rs1942845, P = 0.7256; for rs522819, P = 0.5651; for rs632542, P = 0.9473; for rs485283, P = 0.9777). Among AA and EA women, 122 SNPs in AA women and 61 SNPs in EA women were nominally significantly associated with diabetes risk (Tables S2,  S3) ; however, none of the SNPs showed statistical significance after FDR adjustment.
We further performed replication studies to examine whether the significance of the rs948516 SNP in the PGR gene among HA women could also be identified in the three independent cohorts of various ethnicities. However, we did not see any significant association among Hispanic populations (SIGMA), AA populations (MEDIA), or trans-ethnic populations (DIAGRAM ; Table 3;  Tables S5,S6 ). In addition, we examined whether SNPs in high linkage disequilibrium (r 2 > 0.9) with rs948516 would be associated with diabetes in the SIGMA or MEDIA populations, but found no significant association for any of the SNPs evaluated in the SIGMA or DIA-GRAM samples (Table S7 ). For the PGR gene, the top SNPs were rs7948940 (P = 2.1 × 10 (DIAGRAM; Tables S5, S6 , S8-S10). For sex-stratified analyses, only the DIAGRAM investigators provided the results for only three SNPs on PGR (rs543215, rs481855, rs499590) and none of these showed significant association with diabetes (data not shown).
Discussion
Among the three large samples of AA, HA, and EA women who participated in the WHI, we found that SNPs in the PGR gene were significantly associated with the risk of T2DM in HA women, and the significance of this association was retained after FDR adjustment. However, the significance of the rs948516 SNP was not replicated in the Hispanic population of the SIGMA Type 2 Diabetes Consortium (OR 0.964; P = 0.337). 18 Furthermore, we assessed the rs948516 SNP in sex-combined data from AA populations in the MEDIA Consortium (OR 1.02; P = 0.61) and in the DIAGRAM Consortium (OR 0.971; P = 0.11), 18 and did not identify significant associations. Thus, the observed significant signal in the PGR gene could have been a false positive. However, the large consortiums of GWASs consist of mixed populations, which may be more subject to population stratification and considerable heterogeneity, and thus possible explain the inconsistencies in our results. However, several SNPs other than rs948516 on PGR showed nominally significant associations with diabetes in other populations, such as rs7948940 (P = 2.1 × 10 −3 ) among AA in the WHI and
suggesting that there is also a possibility of "gene effects" instead of "SNP effects". Alternatively, threshold effects may explain the mostly null findings in common variants of the SHP genes, because the effects of these common variants on diabetes may be too small to reach the strict Type I error level of significance. More importantly, it has been suggested that sex hormones may have a different effect on T2DM risk in men and women, 2,4 and these sex-specific effects could not be addressed in our replication analyses. However, this motivates the need for future studies, especially sexspecific analyses, to confirm our findings and clarify the role of SHPs in T2DM.
Previous GWASs have identified more than 50 genetic loci associated with T2DM risk ( SHBG play important roles in the development of T2DM. 1,2 Our classic hypothesis-driven candidate gene approach can complement GWASs by decreasing the number of tests required for statistical power while taking advantage of known biology.
We observed that SNPs located in the upstream region of the PGR gene were strongly and significantly associated with diabetes risk in HA women. In particular, two SNPs in the PGR gene (rs4754732 and rs948516) were significantly associated with T2DM and were in complete linkage disequilibrium with each other. Most likely due to heterogeneities across sexes and different populations and the strict Type 1 error control, the significant effect of SNP rs948516 was not replicated in several consortia of GWAS of T2DM. Therefore, the significant signal observed in the PGR gene in relation to diabetes risk, albeit with strong biological plausibility, needs to be interpreted with caution. Of note, however, proxies of rs948516, such as rs1938953 and rs1942835, have been nominally and significantly associated with insulin sensitivity index (P = 0.001041) 30 and HbA1c level (P = 0.02129), 31 respectively, further supporting a potential functional role of this PGR variant in glucose metabolism. Another study reported that the onset of gestational diabetes typically occurs during the second trimester of pregnancy, when the circulating levels of progesterone are high, suggesting a possible role of progesterone in gestational diabetes. 32 Further, in a retrospective cohort study involving 2081 pregnant women, those receiving a prophylactic intramuscular injection of 17α-hydroxyprogesterone caproate had a 2.9-fold higher risk of gestational diabetes than the risk noted in women who did not receive the injection. 33 An experimental study in mice also demonstrated an active role of PGR in β-cell function, because female mice lacking the PGR had improved glucose tolerance resulting from enhanced insulin secretion. 34 Together, these findings indicate a possible role of the PGR in increasing diabetes risk. Further functional studies illustrating the role of PGR in glucose metabolism are clearly warranted.
Several prospective studies have linked elevated circulating levels of estradiol to an increase in the risk of T2DM in men and women. 2, 35 In addition, previous case-control studies and prospective studies showed a sexually dimorphic relationship between total testosterone levels and T2DM, with an inverse association observed in men and a positive association observed in women. 2, 4 Because androgen and estrogen exert their effects through binding to AR and ERs, respectively, polymorphisms in AR, ERα, or ERβ may be associated with the risk of T2DM. However, in the present study, variants in such genes were not found to be significantly associated with diabetes risk. Further studies are required to understand the roles of these receptors in modulating diabetes risk in both men and women, and to explore potential sex-specific differences.
Previous studies reported several significant associations between variants in the SHBG gene and diabetes risk. In our study involving samples of the WHI population, the SNP in the SHBG gene with the lowest Pvalue was rs6258, which was nominally associated with diabetes risk in EA women (OR 1.85, 95% CI 1.04-3.30, P = 0.03; Table S3 ). The rs6258 SNP has a relatively low MAF, which has been shown to convert Pro 156 into Leu and decrease the binding affinity of testosterone to SHBG, leading to low testosterone levels. Conversely, the SNP with the lowest P-value was rs1641525 (OR 0.97, 95% CI 0.90-1.04, P = 0.35) in AA women and rs9898876 (OR 1.17, 95% CI 0.99-1.40, P = 0.07) in HA women in the WHI. The clinical significance of the rs6258 SNP and other functional SNPs in the SHBG gene warrant further investigation.
The main strength of the present study is the use of high-quality, well-characterized multiethnic samples of AA, HA, and EA women who were prospectively followed in a national cohort. Nevertheless, several limitations need to be kept in mind when interpreting the findings. First, the statistical power to assess less common variants, diabetes risk, and the heterogeneity of diabetes risk across ethnic groups remains marginal given that there are likely differences in allele frequencies, environmental modifiers, and genetic heterogeneity among these samples. Second, sex-stratified analyses were not available in the replication studies. To further clarify the genetic roles of SHPs, sex-specific analyses are needed. Third, considering that all individuals self-identified their ethnicity, population stratification may be a concern, although we did adjust for three principal components of global ancestry. Finally, potential misclassification due to undiagnosed diabetes, albeit most likely non-differential with regard to germline mutations, may have underestimated the magnitude of the genotype-outcome associations observed in the present study.
In conclusion, SNPs in the PGR gene were significantly associated with diabetes risk in HA women in the WHI; however, the findings were not replicated in EA or AA women in the WHI, nor in sex-combined analyses in other studies. Although the significant signal may be a false positive, the findings suggest that further studies, including sex-specific analyses, sequencing, and fine-mapping with special emphasis on the functional loci in genes of pathways that interact with SHPs, may provide further insight into the role of sex hormones in the development of T2DM.
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